The present technology is directed generally to systems and methods for reliably communicating with implanted medical devices using handheld consumer devices and standard communication protocols such as Bluetooth and Bluetooth Low Energy (BLE) operating at the license-free 2.4 GHz frequency band.
Implantable medical devices such as spinal cord stimulators (SCS) for pain relief require radio telemetry for remote control, configuration, and monitoring. Traditionally, such radio telemetry is performed at a band specifically set aside by the Federal Communication Commission for such use, i.e., the Medical Device Radiocommunications Service (MedRadio) band at 401-406 MHz (˜403 MHz). Because of the ubiquity of low cost wireless personal area networks (WPAN) such as Bluetooth and Bluetooth Low Energy (BLE) networks, and the recent proliferation of consumer devices utilizing such networks including smartphones, tablets, and laptops, it is desirable to utilize these consumer devices and networks for radio telemetry with implantable medical devices. This would eliminate the burden and cost of having a separate custom device for communicating with the implantable medical devices given that patients and medical providers would be able to do so using existing consumer devices.
However, because many of these WPANs, such as Bluetooth and BLE, operate in the license-free 2.4 to 2.4835 GHz Industrial, Scientific, and Medical (ISM) band (˜2.4 GHz) as opposed to the much lower ˜403 MHz MedRadio band, designing medical implants with transmitters that can effectively penetrate body tissue and receivers that can capture signals after penetrating body tissue becomes a major challenge. The challenge in designing such 2.4 GHz radiators is exacerbated by the low power and low-profile requirements of the medical implants, the penetration depth required for some implants, which can be as much as several centimeters under the surface of the patient's skin, the extra distance of the remote telemetry unit from the skin surface (which can be several meters), and the need for very reliable telemetry. Accordingly, there remains a need for improved devices and communication techniques in this technology area.
An overview of the disclosed technology and general aspects of the environments in which the disclosed technology operate are described below under Heading 1.0 (“Overview”) with reference to
In several representative embodiments, one signal delivery device may be implanted on one side of the spinal cord midline 189, and a second signal delivery device may be implanted on the other side of the spinal cord midline 189. For example, the first and second leads 131a, 131b shown in
The signal generator 101 can transmit signals (e.g., electrical signals) to the signal delivery devices 130 that up-regulate (e.g., excite) and/or down-regulate (e.g., block or suppress) target nerves. As used herein, and unless otherwise noted, the terms “modulate,” “modulation,” “stimulate,” and “stimulation” refer generally to signals that have either type of the foregoing effects on the target nerves. The signal generator 101 can include a machine-readable (e.g., computer-readable) or controller-readable medium containing instructions for generating and transmitting suitable therapy signals. The signal generator 101 and/or other elements of the system 100 can include one or more processor(s) 107, memory unit(s) 108, signal generation circuitry 114, and/or input/output device(s) 112. Accordingly, the process of providing modulation signals, providing guidance information for positioning the signal delivery devices 130, establishing battery charging and/or discharging parameters, and/or executing other associated functions can be performed by computer-executable instructions contained by, on, or in computer-readable media located at the pulse generator 101 and/or other system components, which may be implanted or external to the patient. Further, the pulse generator 101 and/or other system components may include dedicated hardware, firmware, and/or software for executing computer-executable instructions that, when executed, perform any one or more methods, processes, and/or sub-processes described herein; e.g., the methods, processes, and/or sub-processes described with reference to
The signal generator 101 can also receive and respond to an input signal received from one or more sources. The input signals can direct or influence the manner in which the therapy, charging, and/or process instructions are selected, executed, updated, and/or otherwise performed. The input signals can be received from one or more sensors (e.g., an input device 112 shown schematically in
In some embodiments, the signal generator 101 and/or signal delivery devices 130 can obtain power to generate the therapy signals from an external power source 103. In one embodiment, for example, the external power source 103 can by-pass an implanted signal generator and generate a therapy signal directly at the signal delivery devices 130 (or via signal relay components). The external power source 103 can transmit power to the implanted signal generator 101 and/or directly to the signal delivery devices 130 using electromagnetic induction (e.g., RF signals). For example, the external power source 103 can include an external coil 104 that communicates with a corresponding internal coil (not shown) within the implantable signal generator 101, signal delivery devices 130, and/or a power relay component (not shown). The external power source 103 can be portable for ease of use.
In some embodiments, the signal generator 101 can obtain the power to generate therapy signals from an internal power source, in addition to or in lieu of the external power source 103. For example, the implanted signal generator 101 can include a non-rechargeable battery or a rechargeable battery to provide such power. When the internal power source includes a rechargeable battery, the external power source 103 can be used to recharge the battery. The external power source 103 can in turn be recharged from a suitable power source (e.g., conventional wall power).
Once the implantable signal generator 101 has been positioned within the patient 190, the therapy programs provided by the signal generator 101 can be updated remotely via a wireless physician's programmer (e.g., a physician's laptop, a physician's remote or remote device, etc.) 117, and/or a wireless patient programmer 106 (e.g., a patient's laptop, patient's remote or remote device, etc.). These external devices may also be used to conduct several of the processes described later, e.g., processes for adjusting signal delivery parameters, including via responses to feedback provided by one or more sensors. Generally, the patient 190 has control over fewer parameters than does the practitioner. For example, the capability of the patient programmer 106 may be limited to starting and/or stopping the signal generator 101, and/or adjusting the signal amplitude. The patient programmer 106 may be configured to accept pain relief input as well as other variables, such as medication use.
The spinal cord 191 is situated within a vertebral foramen 188, between a ventrally located ventral body 196 and a dorsally located transverse process 198 and spinous process 197. Arrows V and D identify the ventral and dorsal directions, respectively. The spinal cord 191 itself is located within the dura mater 199, which also surrounds portions of the nerves exiting the spinal cord 191, including the ventral roots 192, dorsal roots 193 and dorsal root ganglia 194. The dorsal roots 193 enter the spinal cord 191 at the dorsal root entry zone 187, and communicate with dorsal horn neurons located at the dorsal horn 186. In one embodiment, the first and second leads 131a, 131b are positioned just off the spinal cord midline 189 (e.g., about 1 mm. offset) in opposing lateral directions so that the two leads 131a, 131b are spaced apart from each other by about 2 mm, as discussed above. In other embodiments, a lead or pairs of leads can be positioned at other locations, e.g., toward the outer edge of the dorsal root entry zone 187 as shown by a third lead 131c, or at the dorsal root ganglia 194, as shown by a fourth lead 131d, or approximately at the spinal cord midline 189, as shown by a fifth lead 131e.
Representative systems and methods of the present technology allow for implanted medical devices such as the implantable signal generator 101 to reliably communicate with handheld consumer devices that can operate in addition to or in lieu of the wireless physician's programmer (e.g., a physician's laptop, a physician's remote or remote device, etc.) 117, and/or a wireless patient programmer 106 (e.g., a patient's laptop, patient's remote or remote device, etc.) using the global license-free 2.4 GHz ISM, band and using common ubiquitous communication protocols such as Bluetooth (BT) and Bluetooth Low Energy (BLE). This can be in addition to or in lieu of using custom-designed receivers operating at the lower ˜403 MHz MedRadio band.
The length of the radiating section 230 (first distance D1), together with the relative permittivity of the medium in which the IFA operates, determines the resonant frequency of the IFA. In order to tune the IFA to a desired resonant frequency, the length of the radiating section 230 is typically kept to about one-quarter of the wavelength of the target signal, where the wavelength depends on the relative permittivity of the medium in which the signal propagates. That is, the wavelength λ=v/f, where v is the velocity of the electromagnetic wave in the associated medium, and f is the frequency. When the electromagnetic wave propagates in free space, v=c=1/√{square root over (μ0ε0)} (speed of light) where μ0 is the permeability of free space (or vacuum permeability) and ε0 is the permittivity of free space (or vacuum permittivity). For example, for an IFA operating in free space and intended to transmit and receive signals at 2.4 GHz, the of the signal is about 122 mm which means that the length of radiating section 230 (first distance D1) needs to be about 30.5 cm. The grounding section 210 acts like an inductive loading of the radiating section 230, where the length of the grounding section 210 determines the amount of inductive loading and thereby adjusts the resonant frequency of the IFA from that estimated above. A second distance D2 between the feed section 240 and ground section 210 is typically kept smaller than a third distance D3 between the feed section and open end of the radiating section 230. The ratio of the second distance D2 to the third distance D3 (or how close the feed section 240 is to the grounding section 210) determines the input impedance of the IFA.
The header section 500 further includes a charging coil 540 that is situated close to one side of the header section; that side will generally be the side that will be oriented towards the closest surface of the skin when the medical device is implanted. Orienting the medical device 350 with the charging coil 540 closest to the surface of the skin allows the wireless charging signals to inductively couple to the charging coil more efficiently than if the charging coil faced away from the closest surface of the skin (i.e., pointed to the main body mass). In at least some embodiments, the IFA is positioned behind and proximate to the charging coil such that it does not interfere with the inductive coupling of the charging coil to the wireless charging transmitter but also such that IFA's gain/directivity is increased (e.g., maximized) in the presence of the charging coil when compared to what the gain/directivity would be in conventional IFAs positioned proximate to a charging coil. That is, the spatial positioning, in an x, y, z direction, of the IFA inside the header 500 is selected to enhance/improve (e.g., maximize) an effective radiation property of the IFA such as the directivity of the IFA at the desired 2.4 GHz frequency band. The charging coils makes the IFA much more broadband (e.g., increases the bandwidth). For example, the IFA can be disposed at a distance to the charging coil, where the distance is selected to enhance an effective radiation property of the IFA, where “selected to enhance a radiation property” refers to positioning the IFA and the charging coil relative to each other such that the radiation property is better than it would be with the IFA alone and/or with the IFA and charging coils of conventional systems. As a result, instead of the IFA acting more like a radiator, it acts more like a coupler where the IFA is configured to couple electromagnetic radiation to the charging coil, and the charging coil is configured to radiate the coupled electromagnetic radiation toward the outer face of the header section (i.e., towards the surface of the skin to allow coupling to a handheld blue-tooth enabled mobile device).
The charging coil can additionally increase the bandwidth of the IFA, allowing the IFA to operate reliably in the entire 2.4 GHz unlicensed band (e.g., 2.4-2.4835 GHz). For example, the charging coil can enhance the standing wave ratio (SWR) or voltage SWR (VSWR) (keeping it under 2:1) or the −3 dB return loss (RL) (e.g., reduce the RL) or another property of the radiated signal to allow the radiated signal to work reliably over the desired communication band. It will be appreciated that although the charging coil is described as enhancing an effective radiation property of the IFA (e.g., directivity, gain, bandwidth, beam width such as 3 dB or half-power beam width, etc.), because the charging coil is acting as a radiator and the IFA as a coupler, the charging coil enhances a radiation property of the combined IFA and charging coil “effective antenna” radiator. That is, when the IFA converts the electrical signal at its feed to electromagnetic radiation, and the charging coil radiates the electromagnetic radiation towards the outer face of the header section, the charging coil enhances a radiation property of the electromagnetic radiation compared to the IFA acting alone with the charging coil absent. The radiator can thus be viewed as the combination of the IFA and the charging coil, unlike in conventional systems (e.g., MedRadio systems) where the radiator is primarily the antenna (e.g., loop or monopole antenna).
In a representative embodiment, the radiating section 530 is positioned a distance L4 in the x direction from the charging coil 540 where the distance L4 is about 2.2 mm. In some embodiments, the distance L4 can be constrained by other header design factors (including the space available in the header for the IFA) requiring the selection of other antenna dimensions such as L2 and L3 given a fixed L4. Additionally, if L4 is reduced to bring the feed section 515 close to the charging coil 540, the coupling coefficient between the IFA elements and the charging coil conductor can increase such that a small deviation in L4 (for example, due to manufacturing tolerances) can lead to a larger variation in the properties of the IFA.
The feed section 515 is fed (i.e., supplied with an electrical current) at feed point 510. Similarly, the grounding section 525 is grounded (i.e., electrically connected to a zero-potential node) at a ground point 520. The feed section 515 can penetrate the metallic base 570 of the header 500 through a first opening 513a. Similarly, the grounding section 525 can penetrate the metallic base 570 of the header 500 through a second opening 513b. The location of the feed section 515 relative to the grounding section 525 (i.e., the third length L3) determines the input impedance of the IFA. In representative embodiments, the third length L3 is smaller than the first length L1 of the radiating section (i.e., the feed section is closer to the grounding section than to the open end of the radiating section 530). In some embodiments, the openings 513a and 513b are insulated with a ceramic insulator. In some embodiments, the grounding and feed sections can be reversed, e.g., the IFA can be fed at the “ground point” 520, making the “grounding section” 525 the feed section, and can be grounded at the “feed point” 510, making the “feed section” 515 the grounding section.
The header section 500 can be encapsulated with medical epoxy to protect the internal components, including the IFA and charging coil. In some embodiments, the epoxy comprises a Loctite M-31 CL Hysol Medical Device Adhesive with a measured relative permittivity of about 3.12 and a measured loss tangent of about 0.04. The higher relative permittivity of the epoxy (compared to the relative permittivity of free space which is 1), together with the higher relative permittivity of muscle tissue (which could be, for example, about 52.7 with loss tangent of 0.2419 and conductivity 1.7 S/m) allow a 2.4 GHz signal to have an effectively shorter wavelength inside the body and inside the epoxy header as compared to when it is in free space. As discussed in the Overview Section 1.0 above, because of this higher relative permittivity, the velocity of the electromagnetic wave in the medium is slower, which results in a shorter wavelength signal. For example, whereas the wavelength of a 2.45 GHz signal is about 122 mm in free space, the same signal would have a wavelength of about 85 mm in a header enclosed by the epoxy fill as disclosed above and surrounded by muscle tissue. As a result, the characteristic dimensions of the IFA structure need not be as large as would be required for an equivalent IFA operating at the same frequency outside the body and not surrounded by medical epoxy. In some embodiments, to communicate using the 2.4-2.4835 GHz ISM band, the radiating section 530 has a first length L1 of about 7 mm, the radiating section 535 has a third length L3 of about 3 mm, the feed section 515 has a second length L2 of about 13 mm, and the grounding section 525 also has a second length L2 of about 13 mm. As described above, because the charging coil enhances the effective directivity and bandwidth of the IFA, the IFA can have dimensions small enough to fit in the header section 500. A small IFA additionally reduces the need to make the IFA conformal to the header section, e.g., to conform to the shape/curvature of the header (or of the housing or outer surface if the IFA is not contained in the header).
In some embodiments, during operation (e.g., when transferring data via a Bluetooth or BLE communication standard or protocol to a mobile handheld device such as a smartphone from the IPG), the IFA receives an electrical signal at the feed point 520. The electrical signal originates from a control circuit (e.g., a microcontroller) contained in the body section (described later with reference to
The communication between the IPG and the mobile device is bi-directional so the mobile device can also transmit Bluetooth or BLE signals to the IPG. When the IPG is in reception mode, the IPG's charging coil 540 receives electromagnetic radiation from an antenna in the mobile device and couples the received electromagnetic radiation to the radiating section of the IFA. As described above, the charging coil and the IFA are configured to work together to enhance properties of the transmitted/received electromagnetic signal. For example, the effective directivity, gain, bandwidth and/or the beam width of the signal radiated by the charging coil can be enhanced/improved based on properties of the coupling between IFA and the charging coil (e.g., directivity/gain increased, bandwidth increased, and beam width decreased). For example, the distance between the charging coil and the IFA, and/or the number of turns, and/or the turns direction of the charging coil, and/or the size (e.g., radius, loop size) of the charging coil, and/or the geometry of the IFA (e.g., length of radiation sections, location of feed point, length of feed and/or grounding section, orientation of the main radiating section relative to the rest of the IFA, etc.) can be varied to vary the properties of the electromagnetic radiation radiated by the charging coil. This can result in effective antenna properties (i.e., properties of the IFA and charging coil taken together) that allow for reliable communication between the IPG and smartphone over the bandwidth in use. For example, for Bluetooth or BLE communication over the 2.4 GHz ISM band, the effective antenna properties can be antenna return loss (or VSWR or reflection coefficient) above a desired threshold over the available communication channels (e.g., for BLE over the 40 2-MHz channels, which includes three advertising channels and 37 data channels).
Referring now to
An external lumped matching network is typically used to match the IFA to 50 ohms. Without matching, the return loss (S11) of the IFA operating at about 2.45 GHz can be about 3 dB, but after matching, the return loss can be better than 20 dB, and the impedance bandwidth can be wider than the bandwidth of the Bluetooth band with a return loss of better than 10 dB at each end of the Bluetooth band. As discussed above, different properties of the charging coil and the IFA (e.g., proximity of charging coil to the IFA) can enhance the properties of the effective antenna such as the return loss, directivity, total radiated power (TRP), or gain over the desired frequency band. In some embodiments, the gain (TRP+directivity) can be better than −20 dBi with the IPG implanted at 20 mm and transmitting a 0 dBm power. Additionally or alternatively, the return loss can be less than 10 dB (or greater than −10 dB if using a negative convention corresponding to the reflection coefficient or S11 scattering parameter) over the desired 2.4 GHz band; the TRP can be larger than −20 dBm with the IPG implanted at a depth of 3 cm and transmitting at 4 dBm over a BLE advertising channel (e.g., channel 39 centered at 2.48 GHz); and, a directivity can be greater than 5 dBi with the IPG implanted at a depth of 3 cm and transmitting at 4 dBm over a BLE advertising channel. In some embodiments, the gain of the effective antenna can be further enhanced (e.g., improved by more than 2 dB) based on the number and orientation of the therapy leads. For example, current can be coupled onto the charging coil and back to the printed circuit board through therapy leads feed pins.
It will be appreciated that although the sections 515, 525, 530, and 535 of the representative IFA are depicted as cylindrical wires in
The interface board 620 can provide a ground node to ground the grounding section 525 (
The interface board 620 can also provide a feed point 510 (
At block 740, the IFA (e.g., the entire IFA), together with the charging coil, can be encapsulated with an epoxy fill. The epoxy fill can protect the IFA and charging coil from the environment inside the human body (and likewise can protect the body from the components in the header) and can also present a higher relative permittivity to the radio signal transmitted by the medical device or the consumer device communicating with the medical device. The higher permittivity of the epoxy, together with the higher permittivity of the human body (such as muscle tissue), allow for the IFA dimensions to be smaller than they would otherwise be were the medical device used outside the body or not encapsulated by epoxy.
At block 750, the feed section and grounding sections of the IFA are coupled from the header section to a body section of the medical device, e.g., through a ceramic insulating section at the metallic base of the header section. The body section includes circuitry to modulate and demodulate signals transmitted or received by the IFA and provides a grounding plane to which the grounded section is connected.
While the present disclosure contains many representative examples, these should not be construed as limitations on the scope of any disclosed systems and/or methods or of what may be claimed, but rather as descriptions of features that may be specific to particular embodiments of particular disclosed methods. Certain features that are described in this document in the context of separate embodiments can also be implemented in combination in a single embodiment. Conversely, various features that are described in the context of a single embodiment can also be implemented in multiple embodiments separately or in any suitable sub-combination. Moreover, although features may be described above as acting in certain combinations and even initially claimed as such, one or more features from a claimed combination can in some cases be excised from the combination, and the claimed combination may be directed to a sub-combination or variation of a sub-combination.
From the foregoing, it will be appreciated that specific embodiments of the present technology have been described herein for purposes of illustration, but that various modifications may be made without deviating from the scope of the technology. Further, while advantages associated with certain embodiments of the technology have been described in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the present technology. Accordingly, the present disclosure and associated technology can encompass other embodiments not expressly shown or described herein.
As used herein, the phrase “and/or,” as in “A and/or B” refers to A alone, B alone, and A and B. As used herein, the terms “generally” and “about” when used to describe numeric values refer to values within 10% of the indicated value.
To the extent any materials incorporated herein by reference conflict with the present disclosure, the present disclosure controls.
The following clauses describe representative implementations of the present technology.
Clause 1. An implantable medical device (IMD), comprising: a header section, comprising: a charging coil disposed proximate to one outer face of the header section; an inverted F antenna (IFA) disposed proximate to the charging coil and further from the outer face of the header section than the charging coil, wherein the IFA comprises a grounding section, a feed section, a first radiating section, and a second radiating section, the first radiating section coupling the grounding section to the feed section, the second radiating section being disposed in a plane parallel to the charging coil and perpendicular to the first radiating section, and the second radiating section being longer than the first radiating section; an epoxy fill encapsulating the charging coil and IFA; and a base section disposed in a plane perpendicular to and below the charging coil; a body section coupled to the header section and housing circuitry; and an insulation section disposed between the base section of the header section and the body section, comprising insulated openings allowing the feed section and the grounding section of the IFA to penetrate the base section of the header section and to electrically couple to the circuitry in the body section.
Clause 2. The implantable medical device of clause 1, wherein the feed section is about 13 mm in length, the grounding section is about 13 mm in length, the first radiating section is about 3 mm in length, the second radiating section is about 7 mm in length, and the second radiating section is disposed between 2 and 3 mm from the charging coil.
Clause 3. The implantable medical device of any of the foregoing clauses, wherein the body section comprises a ground plane disposed along a plane parallel to the base section, and wherein the second radiating section is in a plane parallel to the ground plane.
Clause 4. The implantable medical device of any of the foregoing clauses, wherein the IFA is not conformal to the header section.
Clause 5. The implantable medical device of any of the foregoing clauses, wherein the IFA is configured to couple electromagnetic radiation to the charging coil and the charging coil is configured to radiate the coupled electromagnetic radiation toward the one outer face of the header section.
Clause 6. The implantable medical device of any of the foregoing clauses, wherein the epoxy fill has a relative permittivity that is generally 3.12, and a loss tangent that is generally 0.04 and is composed of LOCTITE M-31CL Hysol Medical Device Adhesive.
Clause 7. The implantable medical device of any of the foregoing clauses, wherein the IFA is disposed at a distance to the charging coil selected to enhance an effective radiation property of the IFA.
Clause 8. The implantable medical device of clause 7, wherein the effective radiation property is an antenna directivity.
Clause 9. The implantable medical device of any of clauses 7 or 8, wherein the antenna directivity is greater than 5 dBi when the implantable medical device is implanted at a depth of 3 cm, the implantable medical device transmits a signal at a power of 4 dBm and a frequency channel corresponding to a Bluetooth Low Energy advertising channel.
Clause 10. The implantable medical device of clause 7, wherein the effective radiation property is an antenna gain.
Clause 11. The implantable medical device of clause 7, wherein the effective radiation property is an antenna half power beam width.
Clause 12. The implantable medical device of clause 7, wherein the effective radiation property is an antenna bandwidth.
Clause 13. The implantable medical device of any of the clauses 7 or 12, wherein the antenna bandwidth corresponds to a bandwidth in which the return loss is less than 10 dB.
Clause 14. The implantable medical device of any of the clauses 7, 12 or 13, wherein the bandwidth in which the return loss is less than 10 dB corresponds to a bandwidth including a frequency range between 2.4 GHz to 2.4835 GHz.
Clause 15. A method of coupling an implantable medical device to a hand-held device, the method comprising: receiving an electrical signal at a feed point of an inverted F antenna (IFA), wherein the IFA is disposed in a header section of the implantable medical device; converting, at the IFA, the electrical signal to electromagnetic radiation; coupling the electromagnetic radiation to a charging coil disposed proximate to one outer face of the header section; and, radiating, by the charging coil, the electromagnetic radiation towards the one outer face of the header section, wherein the charging coil enhances a radiation property of the electromagnetic radiation.
Clause 16. The method of clause 15, further comprising: receiving, at the charging coil, an electromagnetic signal transmitted by the hand-held device; and, coupling the electromagnetic signal to a radiating section of the IFA.
Clause 17. The method of any of the foregoing clauses, wherein the electrical signal transports data to and from a control circuit disposed in a body section of the implantable medical device, wherein the data conforms to a Bluetooth or Bluetooth Low Energy communication protocol.
Clause 18. The method of clause 16, wherein the hand-held device is a mobile phone configured to transmit and receive electromagnetic signals conforming to a Bluetooth or Bluetooth Low Energy communication standard.
Clause 19. The method of clause 15, wherein a first property of the electromagnetic radiation radiated by the charging coil towards the one outer face of the header section is based on a second property of the electromagnetic radiation coupled to the charging coil from the IFA.
Clause 20. The method of any of clauses 15 or 19, wherein the first property is at least one of a directivity, a gain, a bandwidth, or a beam width and the second property is based on at least one of a distance between the IFA and the charging coil, a size of the charging coil, a number of turns of the charging coil, and a size of the IFA.
This application is a continuation of U.S. patent application Ser. No. 16/399,858, entitled “2.4 GHZ RADIO ANTENNA FOR IMPLANTED MEDICAL DEVICES, AND ASSOCIATED SYSTEMS AND METHODS,” filed on Apr. 30, 2019, now issued as U.S. Pat. No 11,147,974, which claims priority to and benefit from U.S. Provisional Patent Application No. 62/665,446, entitled “A 2.4 GHZ RADIO ANTENNA FOR IMPLANTED MEDICAL DEVICES, AND ASSOCIATED SYSTEMS AND METHODS,” filed on May 1, 2018, which is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3871382 | Mann | Mar 1975 | A |
D250719 | Jacobson et al. | Jan 1979 | S |
4379462 | Borkan et al. | Apr 1983 | A |
D280930 | Speicher et al. | Oct 1985 | S |
5144946 | Weinberg et al. | Sep 1992 | A |
D337820 | Hooper et al. | Jul 1993 | S |
D343901 | Anderson | Feb 1994 | S |
5300080 | Clayman et al. | Apr 1994 | A |
5769877 | Barreras, Sr. | Jun 1998 | A |
6104957 | Alo et al. | Aug 2000 | A |
6115634 | Donders et al. | Sep 2000 | A |
6522932 | Kuzma et al. | Feb 2003 | B1 |
6529774 | Greene | Mar 2003 | B1 |
6587719 | Barrett et al. | Jul 2003 | B1 |
D478990 | Kroll | Aug 2003 | S |
6626181 | Knudson | Sep 2003 | B2 |
7047076 | Li | May 2006 | B1 |
7051419 | Schrom et al. | May 2006 | B2 |
D523144 | Wenger et al. | Jun 2006 | S |
7133724 | Greenberg et al. | Nov 2006 | B2 |
7167743 | Heruth et al. | Jan 2007 | B2 |
7295881 | Cohen et al. | Nov 2007 | B2 |
7308303 | Whitehurst et al. | Dec 2007 | B2 |
D559987 | Strother et al. | Jan 2008 | S |
7481759 | Whitehurst et al. | Jan 2009 | B2 |
7489968 | Alexander | Feb 2009 | B1 |
7502652 | Gaunt et al. | Mar 2009 | B2 |
7613524 | Jordan | Nov 2009 | B2 |
7616988 | Stahmann et al. | Nov 2009 | B2 |
7628750 | Cohen et al. | Dec 2009 | B2 |
7650191 | Lim et al. | Jan 2010 | B1 |
D610261 | Strother et al. | Feb 2010 | S |
7822480 | Park et al. | Oct 2010 | B2 |
7991483 | Atanasoska et al. | Aug 2011 | B1 |
D663035 | Smith | Jul 2012 | S |
D665086 | Smith | Aug 2012 | S |
D665087 | Smith | Aug 2012 | S |
8929986 | Park et al. | Jan 2015 | B2 |
D736383 | Park et al. | Aug 2015 | S |
D736930 | Park et al. | Aug 2015 | S |
9162071 | Parramon et al. | Oct 2015 | B2 |
9227076 | Sharma et al. | Jan 2016 | B2 |
9776002 | Park et al. | Oct 2017 | B2 |
10065044 | Park et al. | Sep 2018 | B2 |
11147974 | Sandhu | Oct 2021 | B2 |
20020107554 | Biggs et al. | Aug 2002 | A1 |
20030018368 | Anasarinia | Jan 2003 | A1 |
20030083697 | Baudino et al. | May 2003 | A1 |
20030097165 | Krulevitch et al. | May 2003 | A1 |
20030100924 | Foreman et al. | May 2003 | A1 |
20030114752 | Henderson et al. | Jun 2003 | A1 |
20030120150 | Govari | Jun 2003 | A1 |
20030120322 | Benja-Athon | Jun 2003 | A1 |
20030120323 | Meadows et al. | Jun 2003 | A1 |
20030136418 | Behm | Jul 2003 | A1 |
20030204222 | Leinders et al. | Oct 2003 | A1 |
20040133184 | Hildebrand | Jul 2004 | A1 |
20040186543 | King et al. | Sep 2004 | A1 |
20050033393 | Daglow | Feb 2005 | A1 |
20050075683 | Miesel et al. | Apr 2005 | A1 |
20050113882 | Cameron et al. | May 2005 | A1 |
20050131483 | Zhao et al. | Jun 2005 | A1 |
20050134520 | Rawat | Jun 2005 | A1 |
20050203583 | Twetan et al. | Sep 2005 | A1 |
20050203584 | Twetan et al. | Sep 2005 | A1 |
20070060980 | Strother et al. | Mar 2007 | A1 |
20070111587 | Ries et al. | May 2007 | A1 |
20070270916 | Fischell et al. | Nov 2007 | A1 |
20080097554 | Payne et al. | Apr 2008 | A1 |
20080255631 | Sjostedt et al. | Oct 2008 | A1 |
20080262563 | Sjostedt | Oct 2008 | A1 |
20090012576 | Erbstoeszer et al. | Jan 2009 | A1 |
20090017700 | Zart et al. | Jan 2009 | A1 |
20090018600 | Deininger et al. | Jan 2009 | A1 |
20090228074 | Edgell et al. | Sep 2009 | A1 |
20090248094 | McDonald | Oct 2009 | A1 |
20090248112 | Mumbru | Oct 2009 | A1 |
20090270948 | Nghiem et al. | Oct 2009 | A1 |
20100004721 | Bryce et al. | Jan 2010 | A1 |
20100038132 | Kinney et al. | Feb 2010 | A1 |
20100168818 | Barror et al. | Jul 2010 | A1 |
20100217340 | Watschke et al. | Aug 2010 | A1 |
20100233896 | Dilmaghanian | Sep 2010 | A1 |
20100305663 | Aghassian | Dec 2010 | A1 |
20110087309 | Stypulkowski | Apr 2011 | A1 |
20110106208 | Faltys et al. | May 2011 | A1 |
20110112601 | Meadows et al. | May 2011 | A1 |
20110112610 | Rahman et al. | May 2011 | A1 |
20110270363 | Schramm | Nov 2011 | A1 |
20120101551 | Aghassian et al. | Apr 2012 | A1 |
20120253440 | Grohmann | Oct 2012 | A1 |
20120315798 | Poon et al. | Dec 2012 | A1 |
20130018440 | Chow | Jan 2013 | A1 |
20130066399 | Min | Mar 2013 | A1 |
20130085350 | Schugt | Apr 2013 | A1 |
20130110202 | Grevious | May 2013 | A1 |
20140002314 | Li | Jan 2014 | A1 |
20140002318 | Meulmester | Jan 2014 | A1 |
20180064945 | Park et al. | Mar 2018 | A1 |
20180369595 | Park et al. | Dec 2018 | A1 |
20190232064 | Parker | Aug 2019 | A1 |
20190336776 | Sandhu | Nov 2019 | A1 |
20190336778 | Sandhu | Nov 2019 | A1 |
Number | Date | Country |
---|---|---|
WO-2006131302 | Dec 2006 | WO |
WO-2011094074 | Aug 2011 | WO |
WO-2013067538 | May 2013 | WO |
WO-201 6051206 | Apr 2016 | WO |
Entry |
---|
International Search Report and Written Opinion for International Patent Application No. PCT/US2019/030077, dated Aug. 13, 2019, 11 pages. |
Extended European Search Report and Written Opinion for European Patent Application No. 19796030.5, Applicant: Nevro Corp., dated Jan. 5, 2022, 11 pages. |
Number | Date | Country | |
---|---|---|---|
20220054846 A1 | Feb 2022 | US |
Number | Date | Country | |
---|---|---|---|
62665446 | May 2018 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16399858 | Apr 2019 | US |
Child | 17474023 | US |